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Red ginseng acidic polysaccharide (RGAP), isolated from Korean red ginseng, displays immunostimulatory and antitumor
activities. Even though numerous studies have been reported, the mechanism as to how RGAP is able to stimulate the immune
response is not clear. In this study, we aimed to explore the mechanism of molecular activation of RGAP in macrophages. RGAP
treatment strongly induced NO production in RAW264.7 cells without altering morphological changes, although the activity
was not strong compared to LPS-induced dendritic-like morphology in RAW264.7 cells. RGAP-induced NO production was
accompanied with enhanced mRNA levels of iNOS and increases in nuclear transcription factors such as NF-κB, AP-1, STAT-1,
ATF-2, and CREB. According to pharmacological evaluation with speciﬁc enzyme inhibitors, Western blot analysis of intracellular
signaling proteins and inhibitory pattern using blocking antibodies, ERK, and JNK were found to be the most important signaling
enzymes compared to LPS signaling cascade. Further, TLR2 seems to be a target surface receptor of RGAP. Lastly, macrophages
isolated from RGS2 knockout mice or wortmannin exposure strongly upregulated RGAP-treated NO production. Therefore, our
results suggest that RGAP can activate macrophage function through activation of transcription factors such as NF-κB and AP-1
and their upstream signaling enzymes such as ERK and JNK.
1.Introduction
Korean ginseng (the root of Panax ginseng C.A. Meyer) is a
representative herbal which is ethnopharmacologically well
known in East Asian countries, including Korea, China, and
Japan for about 2,000 years. This plant is indeed widely used
as a supplementary herbal medicine for treating numerous
diseases such as cancer, diabetes, and atherosclerosis [1].
Active constituents of ginseng are reported to be ginseno-
sides, acid polysaccharides, peptides, polyacetylenic alcohols,
and fatty acids [2]. Of these ingredients, ginsenosides have
been known as the major active compounds with a variety
ofpharmacologicalactivitiessuchasantidiabetic, anticancer,
and antiinﬂammatory eﬀects [2–6]. In contrast to the
ginsenosides, pharmacological eﬃcacy of the polysaccharide
fractions has not been fully investigated.
Nonetheless, several studies have demonstrated that
immunostimulatory functions of red ginseng could be due
to red ginseng acid polysaccharide (RGAP) [2]. Thus, it
has been stressed that acid polysaccharides from the root
of Panax ginseng play a critical role in displaying mito-
genic, antitumor, and direct immunostimulating activities in
cyclophosphamide-treated immunosuppressed mice [2, 7–
9]. RGAP was reported to upregulate the functional roles
of natural killer cells and macrophages linked to antitumor
activities [10, 11]. Furthermore, this polysaccharide has been
found to diminish the incidence rate of benzo[a]pyrene-
mediated neoplasms [12].2 Mediators of Inﬂammation
Although previous papers indicated its immunostimu-
latory roles in various immune cells, the exact molecular
mechanism of RGAP in macrophages has not been fully
elucidated. In this study, therefore, we aimed to explore how
RGAP can stimulate functional activation of macrophages
by measuring molecular events and characterizing surface
receptors and also understand how the immunostimulatory
activity by RGAP occurs.
2.MaterialsandMethods
2.1. Materials. RGAP isolated from Korean red ginseng was
performedby steaming and drying fresh ginseng root (Panax
ginseng C.A. Meyer) as described previously [13, 14]a n d
was kindly supplied by the Korea Ginseng Corporation
(Daejeon, Republic of Korea). (3-4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, a tetrazole (MTT), and
lipopolysaccharide (LPS, E. coli 0111:B4) were purchased
from Sigma Chemical Co. (St. Louis, MO). Piceatannol,
SP600125, U0126, PP2, and pam3CSK were obtained from
Calbiochem (La Jolla, CA). β-glucan was puriﬁed from
Lentinus edodes [15]. Foetal bovine serum and RPMI 1640
were obtained from GIBCO (Grand Island, NY). RAW264.7
cells were purchased from ATCC (Rockville, MD). All other
chemicals were of Sigma grade. Phosphospeciﬁc or total
antibodies to p65, c-fos, c-Jun, CREB, extracellular signal-
related kinase (ERK), c-Jun N-terminal kinase (JNK), p38,
Akt, IκBα,γ-tubulin, β-tubulin, and β-actin were obtained
from Cell Signaling (Beverly, MA).
2.2.Animals. RGS2knockoutmice[16]werekindlysupplied
from Dr. Blumber (Washington University, St. Louis, MO).
Wild-type C57BL/6 male mice (6–8 weeks old, 17–21g) were
obtained from DAEHAN BIOLINK (Chungbuk, Republic of
Korea) and maintained in plastic cages under conventional
conditions. Water and pellet diets (Samyang, Daejeon,
Republic of Korea) were available ad libitum. Studies were
performed in accordance with guidelines established by
the Kangwon University Institutional Animal Care and Use
Committee.
2.3. Preparation of Peritoneal Macrophage. Peritoneal exu-
dates were obtained from wild-type or RGS-2 knockout
C57BL/6 male mice (7-8 weeks old, 17–21g) by lavaging
4 days after intraperitoneal injection of 1mL of sterile 4%
thioglycollate broth (Difco Laboratories, Detroit, MI) as
reported previously [17, 18]. After washing with RPMI 1640
medium containing 2% FBS, peritoneal macrophages (1 ×
106 cells/mL) were plated in 100mm tissue culture dishes for
4hat37 ◦Ci na5 %C O 2 humidiﬁed atmosphere.
2.4. Cell Culture. Peritoneal macrophages and RAW264.7
cells were cultured with RPMI 1640 medium supplemented
with 10% heat-inactivated fetal bovine serum (Gibco, Grand
Island, NY), glutamine, and antibiotics (penicillin and strep-
tomycin) at 37◦C under 5% CO2.F o re a c he x p e r i m e n t ,c e l l s
were detached with a cell scraper. Under our experimental
cell density (2 × 106 cells/mL), the proportion of dead cells
Table 1: Sequences of primers used in real-time PCR Analysis.
Gene Primer sequences
iNOS F5  -CCCTTCCGAAGTTTCTGGCAGCAGC-3 
R5  -GGCTGTCAGAGCCTCGTGGCTTTGG-3 
GAPDH F5  -CACTCACGGCAAATTCAACGGCAC-3 
R5  -GACTCCACGACATACTCAGCAC-3 
was less than 1%, according to Trypan blue dye exclusion
tests.
2.5. NO Production. After preincubation of RAW264.7 cells
(1×106 cells/mL) for 18h, cells were treated with RGAP (0 to
4mg/mL)orLPS(1μg/mL) for 24h. The inductive eﬀect of
RGAP on NO production was determined by analyzing NO
levels with the Griess reagent, as described previously [19,
20].
2.6. mRNA Analysis by Semiquantitative Reverse Tran-
scriptase-Polymerase Chain Reaction (RT-PCR). To evaluate
iNOS mRNA expression levels, total RNA was isolated from
LPS-treated RAW264.7 cells with TRIzol Reagent (Gibco
BRL),accordingtothemanufacturer’sinstructions.Thetotal
RNA was stored at −70◦C until use. Semiquantitative RT
r e a c t i o n sw e r ec o n d u c t e da sr e p o r t e dp r e v i o u s l y[ 21, 22].
T h ep r i m e r s( B i o n e e r ,S e o u l ,R e p u b l i co fK o r e a )u s e da r e
indicated in Table 1.
2.7. Preparation of Total Lysates and Nuclear Extracts and
Immunoblotting. Preparation of total lysates and nuclear
extracts from LPS-treated RAW264.7 cells pretreated with
RGAP or LPS was done using a method previously published
[23, 24]. Immunoblotting of phosphorylated or total levels
of transcription factors (AP-1 and p65), MAPK (ERK, p38,
and JNK), IκBα,I K K β, Akt, p85/PI3K, PDK1, γ-tubulin,
and nonreceptor tyrosine kinases (Src and Syk) was done
according to previously published methods [25].
2.8. Statistical Analysis. Data (Figures 1(a), 1(b), 1(d), 2(a),
3, 5,a n d6), expressed as means ± standard deviations (SD),
were calculated from at least three independent experiments,
each performed in triplicate. Other data are representative
of three diﬀerent experiments with similar results. For sta-
tistical comparisons, results were analyzed using analysis of
variance/Scheﬀe’s post hoc test and a Kruskal-Wallis/Mann-
Whitney test. A P<0.05 was considered a statistically
signiﬁcant diﬀerence. All statistical tests were carried out
using the computer program SPSS (SPSS Inc., Chicago, IL).
3. Results and Discussion
Polysaccharides isolated from basidiomycetes have been
reported to act as immunostimulators. The fungal polysac-
charides (e.g., lentinan) originating from Lentinus edodes
is composed of the basic structure of a β-1,3-glucan
with β-1,6-glucopyranosidic branches and has also showed
immunostimulating properties [26–28]. In contrast, RGAPMediators of Inﬂammation 3
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Figure 1: Eﬀects of RGAP and LPS on production of NO and morphological changes. (a, b, and d) Levels of NO were determined by Griess
assay from culture supernatants of RAW264.7 cells treated with RGAP and LPS (1μg/mL) for 24h. (c) Morphological changes in RAW264.7
cells treated with LPS (1μg/mL), RGAP (2mg/mL), and IL-4 (20ng/mL). Images were taken by a digital camera. #P<0.05 and ##P<0.01
compared to normal and ∗P<0.05 and ∗∗P<0.01 compared to control.
has also been found to have immunostimulating and
antitumor activities in tumor-bearing models [11], but the
exact mechanism of these eﬀects was not fully investigated.
As continuous work, therefore, the immunostimulatory
mechanism of RGAP was evaluated using macrophages.
Our previous data indicate that RGAP was capable of
modulatingfunctionalactivationofmacrophages[28].Thus,
this polysaccharide (0 to 4mg/mL) signiﬁcantly induced
NO production, although such induction level was not
higher than LPS exposure (Figure 1(a)) or comparable with
other immunogens such as poly-γ-glutamic acid, lactic acid
bacterium-derived peptidoglycans, and β-glucans [29, 30].
RGAP-induced NO production seemed not to be due to
the contamination of endotoxin, since NO release by RGAP
was not blocked with polymixin B (Figure 1(b)), a cyclic
polycationic peptide antibiotic that binds to anionic lipids
such as LPS [31]. Interestingly, the activation pattern of
macrophages by LPS (1μg/mL) was distinct from that of
RGAP (2mg/mL). For example, the morphological change
of macrophages observed by LPS exposure was not induced
by RGAP and IL-4 (Figure 1(c)). Furthermore, higher con-
centrations of RGAP (4mg/mL) antagonized LPS-induced
production up to 18% (Figure 1(d)), suggesting that the
activation mechanism between LPS and RGAP could be
diﬀerent.
To conﬁrm whether the production of NO by RGAP is
managed by cellular transcription factor activation, levels of
iNOS expression and transcription factors required for iNOS4 Mediators of Inﬂammation
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Figure 2: Eﬀect of RGAP on iNOS mRNA expression of and activation of transcription factors. (a) The mRNA levels of iNOS and GAPDH
weredeterminedbyreal-timePCR.(b)Totalorphosphorylatedlevelsoftranscriptionfactors(NF-κB(p65),AP-1(c-Fosandc-Jun)),CREB,
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or phosphorylated proteins. #P<0.05 and ##P<0.01 compared to normal.
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Figure 3: Eﬀects of enzyme inhibitors on RGAP- or LPS-mediated NO production in RAW264.7cells. (a and b) Levels of NO were
determined by the Griess assay from culture supernatants of RAW264.7 cells pretreated with MAPK inhibitors (U0126 (U0), SB203580
(SB), and SP600125 (SP)), tyrosine kinase inhibitors (PP2, piceatannol (Pic), and AG126 (AG)), LY294002 (LY), and BAY11-7082 (BAY),
after RGAP (1mg/mL) or LPS (1μg/mL) treatment for 24h. ∗P<0.05 and ∗∗P<0.01 compared to control.
gene expression were explored. As Figure 2(a) indicates,
iNOS expression showed similar pattern in both groups,
but RGAP-induced iNOS gene expression was much lower
than LPS group. In particular, the nuclear translocation
levels of phosphorylated or total transcription factors such
as NF-κB (p65), AP-1 (c-Jun and c-Fos), CREB, ATF-2, and
STAT-1 required for iNOS promoter activity [32] was also
seen in both groups. Similar results showing that RGAP
w a sa b l et os t i m u l a t eN F - κB activation in macrophages have
been re- ported previously [33]. However, the levels of these
factors were clearly lowered in the RGAP-treated groups
(Figure 2(b)).
To compare the diﬀerence in transcriptional activation
levels of macrophages between LPS and RGAP, intracel-
lular signaling events were also investigated. As shown
in Figure 3(a), the intracellular signaling patterns seem to
be diﬀerent. Namely, the inhibitory activity of tyrosine
kinase inhibitors such as piceatannol, PP2, and AG490
after RGAP exposure was 2-fold less than after LPS treat-
ment (Figure 3(a)). Interestingly, U0126, an ERK inhibitor,Mediators of Inﬂammation 5
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Figure 4: Eﬀect of RGAP and LPS on the activation of upstream signalling enzymes for NF-κB and AP-1 translocation. (a and b)
Phosphorylated or total protein levels of IκBα, Akt, ERK, JNK, p38, and β-actin from cell lysates prepared with RGAP- or LPS-treated
RAW264.7 cells were determined by phosphospeciﬁc or total protein antibodies.
and SP600125, a JNK inhibitor, signiﬁcantly suppressed
RGAP-mediated NO production (Figure 3(a)), while these
inhibitors did not block eﬀects of LPS in RAW264.7 cells
(Figure 3(b)), suggesting that JNK and ERK positively reg-
ulate RGAP-induced signaling cascades. It has been reported
that MAPK plays a critical role in immunogenicity mediated
by carbohydrate-containing immunogens such as β-glucans
andlacticacidbacterium-deriv edpeptidogly cans[34].These
data also strongly imply that intracellular signaling mech-
anisms are distinct between LPS and RGAP. The involve-
ment of NF-κB, AP-1, CREB, and ATF-2 in RGAP-induced
macrophage activation was also demonstrated by measur-
ing the phosphorylation levels of their upstream signaling
enzymes [35]. For NF-κB signaling, RGAP enhanced the
phosphorylation of Akt and IκBα w i t h i n5t o1 5m i n ,w h i l e
L P So n l ys t r o n g l ye n h a n c e dI κBα at 5min (Figure 4(a)).
According to our report that the phosphorylation of IκBα
at 5min is critically regulated by Syk activity [36], Syk
seems to be required for early activation of NF-κB stimulated
by RGAP and LPS. For MAPK activation, ERK, JNK, and
p38 seemed to be activated at 5min. In contrast, LPS-
induced MAPK signaling events were distinctly seen at 15
to 30min (Figure 4(b)). Therefore, these results strongly
suggest that diﬀerentially activated molecular events in
macrophageinﬂammatoryresponsesbyRGAPandLPSseem
to diﬀerentially control the strength of immune responses
triggered by RGAP or LPS.
Finding the molecular target of RGAP is important
in understanding the molecular mechanism of action for
RGAP-induced immune responses. Considering that RGAP
is not able to penetrate into cell membranes like other
glucose moiety-containing immunogens [37], it is expected
that the target of this polysaccharide is on the surface
membrane. To check this, we employed several blocking
antibodies to TLR2, TLR4, and dectin-1, which are known
to interact with polysaccharide fractions such as β-glucan
and Zymosan [38]. Indeed, antagonistic antibodies to TLR2,
TLR4, and dectin-1 signiﬁcantly suppressed NO production
induced by Pam3CSK (a TLR2 ligand), LPS (a TLR4 ligand),
and β-glucan (a dectin-1 ligand; Figure 5). Intriguingly,
RGAP-induced NO production was greatly diminished by
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Figure 5: Eﬀects of blocking antibodies on RGAP-mediated NO
productioninRAW264.7cells.LevelsofNOweredeterminedbythe
GriessassayfromculturesupernatantsofRAW264.7cellspretreated
with blocking antibodies to TLR2, TLR4, and dectin-1 2h before
stimulation with RGAP, pam3CSK, β-glucan, or LPS (1 μg/mL)
treatment for 24h. ∗P<0.05 and ∗∗P<0.01 compared to control.
the TLR2 antibody, indicating that TLR2 could be a binding
receptor for RGAP (Figure 5).WhetherTLR2antibodybinds
directly bind to RGAP or whether RGAP binding to TLR2 is
blocked,thisantibodytoTLR2requiresfurtherinvestigation.
Finally, even though ginseng has been known to boost
the body’s immune responses, the stimulatory eﬀect of
ginseng polysaccharide fraction was marginal, as assessed by
NO production (Figure 1). Compared to other stimulatory
polysaccharides, we wish to improve the stimulatory activity
of ginseng or ginseng-derived polysaccharide fractions (e.g.,
RGAP). In our screening experiments, we found that RGS2
and wortmannin-targeted enzyme(s) were capable of acting
as negative regulators in RGAP-induced production of NO.6 Mediators of Inﬂammation
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Figure 6: Eﬀects of RGS2 and wortmannin on RGAP-mediated NO
production in peritoneal macrophages. Levels of NO were deter-
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the presence or absence of wortmannin, stimulated with RGAP or
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Thus, peritoneal macrophages from RGS2 knockout mice
strongly enhanced NO production up to 3-fold higher,
compared with primary macrophages from wild-type mice,
while LPS-induced NO production was enhanced 1.5-fold.
Further, wortmannin, an inhibitor of PI3K, polo-like kinase,
and myosin light chain kinase [39, 40], upregulated NO
production stimulated with RGAP but not LPS (Figure 6),
suggesting that a wortmannin-targeted enzyme(s) can act
as a unique, negative regulator of RGAP-mediated signaling
cascade linked to its immunostimulatory activity. The fact
that wortmannin can act as a broad-spectrum enzyme
inhibitor [39, 40] commits us to analyze which wortmannin-
targeted enzyme contributes to its upregulation of RGAP-
induced NO production. Knowing which enzyme involved
in enhancement of this activity may enhance ginseng’s
immunostimulatory eﬀects. Indeed, some components such
as lucidenic acids-rich extracts have been found to improve
the activity of β-glucans and polysaccharides from mush-
rooms [41]. Therefore, future work will be focused on
identiﬁcation of an enzyme acting as a negative regulator.
In summary, we found that RGAP treatment induced
NO production in RAW264.7 cells without altering morpho-
logical changes, unlike LPS. RGAP-induced NO production
was associated with enhanced levels of iNOS and nuclear
transcription factors such as NF-κB, AP-1, and CREB.
Evaluation with speciﬁc enzyme inhibitors, phosphorylation
levels of intracellular signaling proteins, and inhibitory
patterns with antagonistic antibodies suggested that ERK
and JNK were the most important signaling enzymes for
RGAP and TLR2 may be a surface receptor for RGAP. Lastly,
macrophages from RGS2 knockout mice and wortmannin
exposure in RAW264.7 cells demonstrated marked upregula-
tion of RGAP-treated NO production. Therefore, our results
strongly suggest that RGAP can be used as an immunostim-
ulatory remedy via TLR2-mediated functional activation of
macrophages,whichcanbeboostedbywortmannin-targeted
enzymes.
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